Tarsus Pharmaceuticals (TARS) Retained Earnings (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Retained Earnings of $782.8 million for Q1 2026, up 303.16% year-over-year from $194.2 million in Q1 2025, and up 205369.29% quarter-over-quarter from $381000.0 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Retained Earnings (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at $782.8 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 303.16% year-over-year to $782.8 million; the TTM figure through Mar 2026 stood at $782.8 million (up 303.16% YoY), while the FY2025 annual figure was $381000.0, down 99.93% from the prior year.
- Retained Earnings for Q1 2026 stood at $782.8 million, up from $381000.0 in the prior quarter.
- The five-year high for Retained Earnings was $782.8 million in Q1 2026, with the low at -$385.3 million in Q1 2025.
- The 5-year median for Retained Earnings is $381000.0 (2025), against an average of $159.4 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 1924.32% in 2022, then sank 1363713.04% in 2024.
- Tarsus Pharmaceuticals' Retained Earnings stood at $301.7 million in 2022, then slumped by 181.08% to -$244.7 million in 2023, then surged by 338.93% to $584.6 million in 2024, then slumped by 99.93% to $381000.0 in 2025, then jumped by 205369.29% to $782.8 million in 2026.
- Business Quant data shows TARS's Retained Earnings at $782.8 million in Q1 2026, $381000.0 in Q4 2025, and $289000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 799.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 799.43 Mn |
| Mar 31, 2026 | 782.84 Mn |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | -385.33 Mn |
| Dec 31, 2024 | 584.56 Mn |
| Sep 30, 2024 | 574.23 Mn |
| Jun 30, 2024 | -313.68 Mn |
| Mar 31, 2024 | 555.66 Mn |
| Dec 31, 2023 | -244.66 Mn |
| Sep 30, 2023 | 416.42 Mn |
| Jun 30, 2023 | -23,000.00 |
| Mar 31, 2023 | 305.65 Mn |
| Dec 31, 2022 | 301.73 Mn |
| Sep 30, 2022 | -95.16 Mn |
| Jun 30, 2022 | 294.15 Mn |
| Mar 31, 2022 | -66.90 Mn |
| Dec 31, 2021 | 213.40 Mn |
| Sep 30, 2021 | 210.96 Mn |